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Summary
Cells require nucleotides to support DNA replication and to repair damaged DNA. In addition to 
de novo synthesis, cells recycle nucleotides from the DNA of dying cells or from cellular material 
ingested through the diet. Salvaged nucleosides come with the complication that they can contain 
epigenetic modifications. Since epigenetic inheritance of DNA methylation mainly relies on 
copying of the modification pattern from parental strands1-3, random incorporation of pre-
modified bases during replication could have profound implications for epigenome fidelity and 
yield adverse cellular phenotypes. Although the salvage mechanism of 5-methyl-2′deoxycytidine 
(5mdC) has been investigated before4-6, currently it remains unknown how cells deal with the 
recently identified oxidised forms of 5mdC – 5-hydroxymethyl-2′deoxycytidine (5hmdC), 5-
formy-2′deoxycytidine (5fdC) and 5-carboxyl-2′deoxycytidine (5cadC)7-10. Here we demonstrate 
that enzymes of the nucleotide salvage pathway display substrate selectivity, effectively protecting 
newly synthesized DNA from the incorporation of epigenetically modified forms of cytosine. Thus 
cell lines and animals can tolerate high doses of these modified cytidines without any deleterious 
effects on physiology. Interestingly, by screening cancer cell lines for growth defects following 
exposure to 5hmdC, we unexpectedly identify a subset of cell lines where 5hmdC or 5fdC 
administration leads to cell lethality. Using genomic approaches we discover that the susceptible 
cell lines overexpress cytidine deaminase (CDA). CDA converts 5hmdC and 5fdC into variants of 
uridine that are incorporated into DNA, resulting in accumulation of DNA damage and ultimately, 
cell death. Our observations extend current knowledge of the nucleotide salvage pathway by 
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revealing the metabolism of oxidised epigenetic bases, and suggest a therapeutic option for 
cancers, such as pancreatic cancer, that have CDA overexpression and are resistant to treatment 
with other cytidine analogues11.
Modified cytidines can enter deoxynucleotide pools, because salvage and nutrient uptake 
pathways can recover nucleosides, rather than simpler degradation products such as uric acid 
in the salvage of purines12. Previous biochemical work suggested that 5mdC is not 
incorporated in the DNA, but is salvaged as thymidine4-6. Salvage of oxidised 5-
methylcytosine (5mCyt) variants has not been previously characterised. We rationalised that, 
if nucleosides are recovered in un-phosphorylated forms (through import) or monophosphate 
forms (through intracellular hydrolysis), the barrier restricting their incorporation into the 
DNA may lie in the nucleotide salvage enzymes or DNA polymerases. Providing cells with a 
final substrate for DNA polymerases, in the form of deoxynucleoside triphosphate, would 
allow decoupling of DNA synthesis from salvage enzyme activity. Therefore, we transfected 
two human cancer cell lines - MDA-MB-231 and H1299 with 5-
hydroxymethyl-2′deoxycytidine triphosphate (5hmdCTP), isolated DNA and analysed base 
composition by HPLC-UV, which was calibrated with a set of nucleoside standards (Fig. 
1a). After 5hmdCTP transfection, two additional nucleosides were observed in the 
hydrolysed DNA that correspond to 5hmdC and 5hmdU (Fig. 1b, c, Extended Data Fig. 1b). 
This indicates that DNA polymerases can incorporate 5hmdC into DNA and also 
demonstrates strong deaminase activity acting on either the nucleotide or on the incorporated 
base, resulting in the presence of 5hmUra in the DNA. The capacity for DNA polymerases 
to use 5hmdCTP was also evident in an in vitro replication assay13 (Fig. 1d), demonstrating 
that human DNA polymerases are not selective against the incorporation of 5hmdC into 
DNA. Therefore, if salvage pathways can convert pre-existing sources of 5hmdC into their 
nucleotide triphosphate forms, this could result in their incorporation into cellular DNA and 
potentially lead to deleterious effects on the epigenome.
The final triphosphate form of cytidine in a cell is produced by sequential phosphorylation 
by three classes of cytidine kinases. First, deoxycytidine kinase (DCK) produces a 
monophosphate, which is then converted into a diphosphate by cytidine monophosphate 
kinases (CMPK1, CMPK2), and subsequently into a triphosphate by the family of 
nucleoside diphosphate kinases (NDPKs)14. Since NDPKs phosphorylate both purine and 
pyrimidine nucleosides15, and CMPK2 is found in the mitochondria16, we directed our 
efforts on examining the substrate selectivity of DCK and CMPK1. Recombinant DCK was 
able to transfer the phosphate from ATP[γ-32P] to 5mdC, 5hmdC and 5fdC, but not 5cadC 
(Fig. 1e, Extended Data Fig. 1d), while CMPK1 phosphorylated only unmodified cytidine 
monophosphate (Fig. 1e). In agreement with previous work on 5mdC4, we can conclude that 
the inability of CMPK1 to create diphosphates of modified nucleotides provides the main 
barrier to the formation of respective dCTPs, limiting their availability for DNA 
polymerases, which can instead accept modified dCTPs.
Given this inherent selectivity of the nucleotide salvage pathway kinase CMPK1 for 
unmodified cytidine, we hypothesized that the introduction of abundant biologically 
modified cytidine variants would have little adverse effect on the physiology of a cell, unless 
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they significantly impaired nucleotide metabolism. First, we determined that biological 
cytidine variants retain 70-100% of their original form after incubation in water and cell 
culture media for 10 days at 37°C, while 80% of the synthetic variant 5-aza-2′deoxycytidine 
(5azadC) decomposed by day 2 in agreement with previous observations17 (Extended Data 
Fig. 2a,b,c). Next, a panel of 19 human cell lines was selected, sampling various tissue 
origins and p53 mutation statuses (Extended Data Fig. 2d)18. When cell growth media was 
supplemented with 10 μM 5hmdC or dC, the majority of the cell lines continued to 
proliferate at a normal rate. However, two cell lines (HOP-92 and MDA-MB-231) 
unexpectedly ceased to proliferate in presence of 5hmdC (Fig. 2a). 10 μM 5hmdC was lethal 
and 1 μM 5hmdC caused mild growth inhibition (Fig. 2b). Interestingly, 5fdC was more 
potent at 1 and 10 μM doses in the MDA-MB-231 cell line, but displayed the same cell line 
selectivity as 5hmdC (Fig. 2b).
Genetic alterations or gene expression differences could modify the response of a cell line to 
biologically modified cytidine variants. By comparing the existing gene expression profiles 
of the cell lines (NCI60 and CCLE projects19,20) that we established as sensitive to modified 
cytidine variants to two randomly chosen resistant ones, we identified 1380 differentially 
expressed genes (p<0.01, >2-fold change). Interestingly, by focussing on differentially 
expressed genes known to be in involved in nucleoside metabolism, we identified cytidine 
deaminase (CDA) overexpression in the 5hmdC sensitive cell types, which had the 9th 
lowest p value of all the genes (Fig. 2c, Extended Table 1). Importantly, none of the other 
known genes involved, either in nucleoside transport or cytidine recycling, were 
differentially expressed (Fig. 2c). To identify other cell lines with CDA overexpression, we 
ranked the 21 available cell lines according to their CDA mRNA levels (Fig. 2d). SN12C 
and Capan-2 cell lines had the highest CDA expression, which was confirmed at the protein 
level by Western blot (Fig. 2e). Examination of 5hmdC and 5fdC tolerance revealed that a 10 
μM dose substantially inhibited the growth of both cell lines, suggesting that the expression 
level of CDA is predictive of cytotoxicity for these epigenetic cytidine variants (Fig. 2e).
To determine whether CDA overexpression is necessary for selective cytotoxicity, we 
manipulated CDA levels in the identified cell lines. Cell lines (MDA-MB-231 and SN12C) 
with stable shRNA knock-down of CDA were able to survive 10 μM 5hmdC (Fig. 3a, 
Extended Data Fig. 2e). Furthermore, stable overexpression of CDA in normally 5hmdC-
resistant cell lines (H1299 and MCF-7) induced substantial growth inhibition (Fig. 3b, 
Extended Data Fig. 2f). These experiments clearly established that CDA overexpression is 
predictive, necessary and sufficient for cytotoxic activity. In vitro measurements of 
recombinant CDA protein activity were performed with various cytidine variants. First, we 
determined that CDA deaminates 5mdC, 5hmdC and 5fdC, but not 5cadC, creating 
thymidine and respective variants of uridine (Extended Data Fig. 2g, h). Second, reaction 
kinetic data fitted well with a pseudo zero-order kinetics model (R2>0.9) revealing that, after 
dC, the second best substrate (i.e. second highest kcat) for CDA is 5fdC (Fig. 3c, d, Extended 
Data Fig. 2h). This was unexpected, because the catalytic activity does not follow a simple 
relationship with the dimensions of the 5′ modification as it does in the case of AID and 
APOBEC enzymes21. Molecular docking of cytidine variants to the CDA structure22 
suggested that 5fdC docks to the catalytic site with nearly 180° rotation when compared to 
unmodified cytidine, retaining the amino group position close to the active site containing 
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Zn2+ (Extended Data Fig. 3a). Contrary, 5hmdC docks in the active site by displacing the 
amino group, which provides a potential explanation for the lower catalytic turnover 
observed (Extended Data Fig. 3a).
The deamination of dC and 5mdC results in dU and T, which are the normal precursors for 
thymidine triphosphate (TTP) synthesis. Conversely, deamination of 5hmdC and 5fdC 
produces 5hmdU and 5fdU, respectively, which are not canonical nucleosides. When 
phosphorylated and incorporated into DNA, 5hmdU and 5fdU are toxic to the cells 
(Extended Data Fig. 3b) as they are recognized as damaged bases and trigger extensive 
uracil glycosylase activity resulting in DNA breaks23. Therefore, we asked whether the 
uptake of 5hmdC in CDA overexpressing cells leads to its conversion into 5hmdU and to its 
incorporation into DNA, potentially explaining cell type specific lethality. First, we 
determined activities of thymidine kinase (TK) and thymidylate kinase (DTYMK) on 
5hmdU and 5fdU. In contrast to the inability of CMPK1 to act on equivalent cytidine 
variants, TK and DTYMK phosphorylated both uridine variants (Fig. 3e). Notably, the 
corresponding triphosphates are not substrates nor potent inhibitors of dUTPase, a robust 
enzyme that removes dUTP from cells (Extended Data Fig. 3c). Finally, analysis of the 
genomic DNA composition of 5hmdC and 5fdC treated MDA-MB-231 cells identified 
5hmUra and 5fUra, but no detectable change in 5hmCyt or 5fdCyt levels in the DNA (Fig. 
3f, Extended Data Fig. 3d, e and Extended Data Fig. 4a, b, c). Overall, in all the cell lines 
examined, a linear correlation was observed between CDA expression and the amount of 
5hmdU in the DNA after treatment with 5hmdC (Extended Data Fig. 4d). Signs of extensive 
DNA damage were detected by phosphoH2AX staining in 5hmdC-treated CDA 
overexpressing cells (MDA-MB-231). In contrast, a cell line expressing low level of CDA 
(H1299) had no obvious phospho-H2AX (Fig. 3g and Extended Data Fig. 5c, d). Also, 
increased numbers of cells in S and G2 phases of the cell cycle were observed in CDA 
overexpressing cell lines, consistent with cell cycle arrest triggered by a DNA damage 
response (Extended Data Fig. 5a). We did not observe deviations in the dNTP pools of 
treated cells, indicating that the cell death is likely to be caused by extensive base excision 
by SMUG1 DNA glycosylase, which recognises 5hmUra and 5fUra triggering repair and 
DNA double stranded breaks (Extended Data Fig. 6). Together, these observations 
demonstrate that CDA deaminates 5hmdC and 5fdC creating 5hmdU and 5fdU 
(respectively), which are incorporated into the DNA, leading to cell cycle arrest and 
eventually death.
CDA overexpression has been linked to resistance to cytidine analogues – such as 
gemcitabine, cytosine arabinoside or 5-azacytidine – that are currently used in cancer 
treatment, presenting a major obstacle to their use11,24-26. Our observations regarding 
biological nucleoside variants demonstrate an opposite effect: CDA overexpression 
sensitises cells to otherwise non-toxic 5hmdC and 5fdC. Since cancers originating in the 
pancreas27, stomach, testis and vagina have up-regulated CDA expression28 (Extended Data 
Fig. 7a, b), we postulated that administration of 5hmdC and 5fdC could have a selective 
activity against these tumour cells. We first tested whether cytotoxic activity is cell 
autonomous for CDA overexpressing H1299 cells in the presence of wild type (wt, CDA 
low) H1299 cells. Both 5hmdC and 5fdC were able to selectively eliminate CDA 
overexpressing cells, suggesting that secreted CDA or 5hmdU is insufficient for cytotoxicity 
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(Fig. 4a). Tolerance to and stability of 5hmdC and 5fdC in vivo was determined in 
immunocompromised BALB/cOlaHsd-Foxn1nu/nu mice after they received a range of doses 
(12.5 mg/kg to 100 mg/kg) of 5hmdC and 5fdC by intraperitoneal injection. Half an hour 
after injection, we were able to detect 5hmdC and 5fdC in the bloodstream, and to quantify 
5hmdC using RapidFire MS (Extended Data Fig. 7c, d). We observed no adverse effects on 
behaviour, injection site, weight or histology in the panel of tissues studied, even though 
some tissues (kidney and intestine) express CDA (Extended Data Fig. 7e, f, g, h, data not 
shown). To determine whether cytidine variants have an effect on tumour growth in 
proliferating cells, we subcutaneously injected H1299 wt and CDA overexpressing cells into 
each side of an animal, which was later treated with 5hmdC or 5fdC (Fig. 4b). Xenografts 
with CDA overexpression grew slightly slower (reaching 64% of wt tumour volume), and 
the volume of the tumour was further reduced 2-fold in animals treated with 5hmdC or 5fdC 
(Fig. 4c). CDA-overexpressing tumours showed a 2-fold decrease in the number of 
proliferating cells and a 3-fold increase in the number of cells with DNA damage in 5fdC-
injected animals, but smaller differences in animals that were 5hmdC-injected (Fig. 4d). 
Similar CDA-dependent effects on tumour volume and proliferation were observed when 
SN12C wt and SN12C CDA knock-down cells were used in the xenograft assay (Extended 
Data Fig. 8).
Here, we have characterised the metabolism of newly discovered biologically modified 
nucleosides, leading to a model in which the selectivity of CMPK1 prevents random 
incorporation of modified cytosines (Fig. 4e). Interestingly, we have discovered that 5hmdC 
and 5fdC, but not 5cadC, are deaminated by CDA at different rates, resulting in the cytotoxic 
5hmdU and 5fdU. Our data on oxidised epigenetic bases is similar to the proposed 
mechanism of 5mdC salvage, in which CMPK1 is rate limiting in the production of the 
diphosphate, whereas 5mdC deamination produces a normal T4-6. We did not observe any 
adverse effects during the administration of 5hmdC and 5fdC in mice, presumably because 
the cytotoxic threshold is only reached in highly proliferating and CDA overexpressing cells, 
in which there is substantial incorporation of nucleoside variants in the DNA, reflected by 
the CDA-dependent regression of xenografts. Together with recent publications 
demonstrating the importance of and therapeutic opportunities targeting MTH1, which 
surveys damaged nucleosides29,30, our data extend the current understanding of the 
metabolism of biological cytidine variants and provide a novel avenue for cancer therapy.
Methods
Purification of DCK, CMPK1, CDA, TMPK and DUT
Human DCK with a C-terminal 6xHis tag was cloned in pET28a(+) and expressed in E. coli 
BL21 RIPL (Life Technologies) for 4 hrs at 37°C following induction with 1 mM IPTG in 
LB. The bacterial pellet was resuspended in 50 mM sodium phosphate pH 8, 300 mM NaCl 
and protease inhibitors (Complete EDTA-free, Roche). The protein was bound to a Hi-
TRAP HP 5 ml column (GE Healthcare) and eluted with a linear gradient of 0-500 mM 
imidazole in the lysis buffer, supplemented with 10% glycerol. The fractions were assessed 
by electrophoresis and ones containing the protein were pooled, concentrated with Amicon 3 
kDa centrifugal filter units (Millipore) and separated on a HiPrep 16/60 Sephacryl S-200 gel 
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filtration column (GE Healthcare). The protein was again concentrated using Amicon 
columns, supplemented with final 10 mM DTT and 40% of glycerol, snap frozen and stored 
in aliquots at −80°C. Human CMPK1 was tagged at the C-terminus with 6xHis and purified 
using a similar workflow to DCK with the following exceptions: the lysis buffer was 50 mM 
Tris pH 7.5, 10 mM NaCl and protease inhibitors (Complete Mini, Roche); after the gel 
filtration step the protein was bound to an anion exchange column HiTrap Q HP 5 ml (GE 
Healthcare) and eluted with a 20 column volumes linear gradient of 0-1 M NaCl. The salt 
was removed by dialysis in 50 mM Tris pH 8, the protein concentrated and 10 mM DTT 
added to the final preparation, prior to storage in 40% glycerol at −80°C. C-terminal 6xHis 
tagged CDA was purified in a similar workflow to CMPK1 with the following 
modifications: the protein was expressed for 19h at 37°C; the lysis buffer was 50 mM Tris 
pH 7.5, 1 mM DTT, 1 mM EDTA and protease inhibitors (Complete Mini, Roche); 
following HiTRAP purification, 6xHis tag was cleaved by thrombin (Sigma); cleaved tag 
and un-cleaved protein was removed by separation using a HiTRAP HP 5 ml column and 
collection of the flow-through. Subsequently, the protein was purified using gel filtration as 
indicated above and stored in aliquots at −80°C. Protein purity was assessed by 
electrophoresis and CDA was additionally identified by MS. Human TMPK1 with a C-
terminal 6xHis tag was cloned in pET28a(+) and expressed in E. coli BL21 RIPL (Life 
Technologies) for 4 hrs at 37°C following induction with 1 mM IPTG in LB. The bacterial 
pellet was resuspended in 50 mM sodium phosphate pH 7, 300 mM NaCl and protease 
inhibitors (Complete EDTA-free, Roche) and lyzed with a French press (EmulsiFlex C5, 
Avestin) at 15000 psi equipped with a recirculating cooler (F250, Julabo) set at 4°C. The 
protein was bound to a Hi-TRAP HP 5 ml column (GE Healthcare) and eluted with a linear 
gradient of 0-500 mM imidazole in the lysis buffer, supplemented with 10% glycerol. The 
fractions were assessed by electrophoresis and ones containing the protein were pooled, 
concentrated with Amicon 3 kDa centrifugal filter units (Millipore), supplemented with 40% 
of glycerol, snap frozen in aliquots and stored at −80°C. Human DUT with a C-terminal 
6xHis tag was cloned in pET28a(+) and expressed in E. coli BL21 RIPL (Life Technologies) 
for 4 hrs at 37°C following induction with 0.2 mM IPTG in LB. The bacterial pellet was 
resuspended in 20 mM sodium phosphate pH 7.3, 150 mM NaCl, 1% Triton X-100 and 
protease inhibitors (Complete EDTA-free, Roche) and lyzed with a French press 
(EmulsiFlex C5, Avestin) at 15,000 psi equipped with a recirculating cooler (F250, Julabo) 
set at 4°C. The protein was bound to a Hi-TRAP HP 5 ml column (GE Healthcare) and 
eluted with a linear gradient of 0-500 mM imidazole in the lysis buffer, supplemented with 
10% glycerol. The fractions were assessed by electrophoresis and ones containing the 
protein were pooled, concentrated with Amicon 3 kDa centrifugal filter units (Millipore), 
supplemented with 40% of glycerol, snap frozen and stored in aliquots at −80°C. TK was 
purchased and the purity assessed by SDS PAGE (8180-TK-050, R&D Systems).
Nucleoside stability
Nucleosides were obtained from the following sources: 5hmdC (PY-7588, Berry & 
Associates), 5fdC (PY-7589, Berry & Associates), 5cadC (PY-7593, Berry & Associates), 
5AZAdC (A3656, Sigma Aldrich), ATP solution (Thermo Fisher), [γ-32P] ATP (Perkin 
Elmer), dC (Sigma Aldrich, D3897), dCMP (Sigma Aldrich, D7625), 5hmdCTP (Bioline, 
BIO-39046). 100 μM solutions of 5hmdC, 5fdC and 5AZAdC were prepared in HPLC grade 
Zauri et al. Page 6









water (Thermo Fisher) or in DMEM medium (Lonza). The solutions were incubated at 37°C 
for 10 days. A sample was taken every 24 h and subjected to HPLC-UV analysis.
Enzyme assays
The substrate selectivity of DCK and CMPK1 kinases were measured by 32P transfer and 
detection using one (1D) or two (2D) dimensional thin layer chromatography (TLC). 1 μg of 
DCK kinase was incubated in 100 mM Tris pH 7.5, 100 mM KCl, 10 mM MgCl2, 1 mM 
[γ-32P] ATP and 200 μM of the respective nucleoside in a 50 μl reaction volume at 37°C for 
2 h. 1 μl of products was separated via 2D TLC on glass-backed AVICEL cellulose plates 
(Analtech) as described31. CMPK1 was assayed through a coupled assay with DCK 
following the conditions described in 32 with 1 μg DCK, 1 μg CMPK1 and 1 mM substrate. 
TK (8180-TK-050, R&D Systems) and TMPK1 were assayed through a coupled assay with 
1 μg TK, 1 μg TMPK1 and 1 mM substrate in 50 mM Tris pH 7.4, 50 mM KCl, 5 mM 
MgCl2, 1 mM ATP and 2.5 μCi [γ-32P] ATP at 37°C. 1D TLC was performed using glass-
backed TLC sheets (PEI cellulose F, Millipore) as described before32. The plates were 
exposed to storage phosphor screen (GE Heathcare), which was scanned using 
Phosphoimager (Biorad) and images analysed with ImageLab software (Biorad). CDA 
kinetic activity data was collected as described33 by monitoring the absorbance at 260 nm 
with a spectrophotometer (SpectraMax M2, Molecular devices) using 45 ng of enzyme (500 
ng for 5hmdC) and the data fitted according to pseudo zero order Michaelis-Menten enzyme 
kinetic model by Prism software (GraphPad). 1 μg DUT was assayed in 50 mM Tris pH7.5, 
4 mM MgCl2, 1 mM DTT, 0.1 mg/ml BSA with 5 μM of substrate in 40 μl reaction volume 
for 10 min at 37°C. The generated pyrophosphate was detected with a bioluminescent 
coupled assay (PPiLight™ inorganic pyrophosphate assay LT07-500, Lonza). The plate was 
then read in a GloMax instrument (Promega).
Molecular docking
A tetramer was generated with CDA structure 1MQ034 and subject to DockPrep in Chimera 
1.8 (www.cgl.ucsf.edu/chimera). Substrates were dC (ZINC18286013)35, 5hmdC 
(ZINC77300654)35 and 5fdC (CSID:10291642) (www.chemspider.com) downloaded 
as .mol files and subjected to .mol2 files conversion in Chimera. Docking was subsequently 
performed with SwissDock (www.swissdock.ch/docking)36. The model with the lowest ΔG 
of ligand was then visualized and analysed with Chimera.
In vitro replication assay
The assay was carried out following protocols for nuclear extract and cytoplasmic fraction 
preparation and for the replication assay37,38. The reaction contained 0.3 mM of each 
canonical nucleotide, except dCTP which was substituted by 5hmdCTP. The reaction was 
stopped with the addition of 0.1 M EDTA final. DNA was extracted with phenol chloroform, 
treated with RNase A/T1 (Thermo Fisher) and free nucleotides removed with a Mini Quick 
Spin DNA column (Roche) prior to HPLC assay.
Zauri et al. Page 7










The single stranded DNA oligonucleotide substrates (5′-FAM 
CATAAAGTGXAAAGCCTGGA, where X = Ura, 5hmUra or 5fUra) were purchased from 
AtdBio and their complementary strand from IDT (all HPLC purified). Recombinant human 
SMUG1 (NEB) was incubated with annealed oligonucleotides as described before39. The 
reaction products were resolved on a 15% denaturing polyacrylamide TBE-Urea gel 
(Invitrogen) and quantified using ChemiDoc (BioRad) with blot detection protocol for Alexa 
488.
Quantitation of nucleosides by HPLC
Genomic DNA was extracted with Gene Jet Genomic DNA extraction Kit (Thermo Fisher) 
or TRI Reagent (Sigma Aldrich), incubated with RNase A/T1 (Thermo Fisher) in buffer 2 
(NEB), phenol/chloroform extracted and precipitated with ethanol. 1-10 μg of DNA was 
hydrolysed as described before40. Nucleosides were resolved with an Agilent UHPLC 1290 
instrument fitted with Eclipse Plus C18 RRHD 1.8 μm, 2.1×150 mm column and detected 
with Agilent 1290 DAD fitted with a Max-Light 60 mm cell. Buffer A was 100 mM 
ammonium acetate pH 6.5, buffer B was 40% acetonitrile, and the flow rate 0.4 ml/min. The 
gradient was between 1.8-100% of 40% acetonitrile with the following steps: 1-2 min, 100% 
A; 2-16 min 98.2% A -1.8% B; 16-18 min 70% A – 30% B; 18 -20 min 50% A- 50 % B; 
20-21.5 min 25% A 75% B; 21.5-24.5 min 100% B.
Quantitation of nucleotides by HPLC
MDA_MB_231 and H1299 treated with 10 μM dC, 10 μM 5hmdC and 1 μM 5fdC. 
Metabolites were extracted at day three as described before41. Briefly, cells were washed in 
PBS and scraped on ice. The pellet was washed again in cold PBS and extraction was done 
with 50 μl of ice cold 50% ACN per mg of pellet. The samples were vortexed and incubated 
on ice for 10 min. Insoluble material was pelleted at 20000 g for 10 min and supernatants 
were dried using a SpeedVac (Thermo Scientific). Metabolites were dissolved in 30 μl of 
buffer A and 20 μl was used for chromatography. HPLC was performed as described41 with 
some minor modifications as listed below. Nucleotides were resolved with an Agilent 
UHPLC 1290 instrument fitted with Eclipse Plus C18 RRHD 1.8 μm, 2.1×150 mm column 
and detected with Agilent 1290 DAD fitted with a Max-Light 60 mm cell at 254, 260 and 
280 nm. Buffer A consisted of 100 mM KH2PO4 (60221, Sigma) with 8 mM 
tetrabutylammoniumbisulfate (98479, Sigma) set at pH 5.5. Buffer B consisted of Buffer A 
with 25 % MeOH. After 8 min at 0% buffer B, the gradient started with a linear increase of 
buffer B to 35% in 19 min, followed by a linear increase from 35% to 38% buffer B in 5 min 
and from 38% to 100% buffer B in 22 min. After an 8 min hold at 100% Buffer B, the 
gradient was reversed from 100% to 0% buffer B in 2 min, followed by a hold at 0% buffer 
B for 2 min. The column temperature was set at 30°C and the flow rate was 0.4 ml/min. The 
compounds were identified by comparing their retention times and their UV spectra with 
those of known standards, which were purchased from Sigma-Aldrich. The integrated area 
was used to quantify the relative abundance of nucleotides by normalizing each peak area to 
the ADP area as an indication of loaded amount.
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Cell culture and transfections
Cell lines were routinely tested for mycoplasma contamination using Lonza Mycoalert Kit. 
Cell proliferation assays were done by seeding cells in p60 plates or in a T25 flask with 
appropriate concentrations of 5hmdC, 5fdC or dC in the growth media. The cells were 
passaged, counted and the media was replaced every two days. Before counting, 1 volume of 
Trypan blue solution (Lonza) was added to an aliquot of single cell suspension. The live 
cells were counted by TC-20 Cell Counter (Bio-Rad). NTPs were introduced by 
nucleofection. 106 MDA-MB-231 cells were nucleofected with 50 mM 5hmdC in a 100 μl 
volume using an Amaxa nucleofector kit (Lonza), following the manufacturer’s instructions. 
After transfection, cells were seeded in a 6 well plate, 24 h later washed twice with PBS, and 
48 h later DNA extracted for HPLC analysis.
Production of stable cell lines
Stable cell lines were generated via lentiviral infection using a standard protocol42 with 2nd 
generation packaging plasmids (pCMV-VSVG, pCMV-dR8.9, a generous gift from Bruno 
Amati, IIT, Milan). CDA knock-down was achieved by infecting MDA-MB-231 and SN12C 
cell lines with pLKO.1 vectors containing 5 different shRNA constructs (SHCLND-
NM_001785, Sigma-Aldrich) and a control pLKO.1 containing shRNA silencing Luciferase 
(a gift from Xin Lu, Oxford Ludwig Cancer Research). Infected cells were selected by 
incubation with 1.5 μg/ml puromycin (Sigma) for 60 hrs. Two cell lines with the lowest 
CDA mRNA (shRNA TRCN0000051290 and TRCN0000051288) levels were further 
assessed by immunoblotting and used for experiments. Lentivirus for CDA overexpression 
was generated with pLenti-puro (39481, Addgene, Ie-Ming Shih laboratory) expressing 
dsRed-IRES-CDA. H1299 and MCF-7 were infected as above. Infected cells were selected 
with puromycin at 2 μg/ml for 60 hrs.
Immunoblotting, FACS and immunofluorescence
For Western blot analysis, 106 cells were lysed with RIPA buffer (20 mM HEPES at pH 7.5, 
300 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, supplemented with protease 
inhibitors (Complete EDTA-free, Roche)) and sonicated. Cleared lysates were 
electrophoresed and immunoblotted with the following primary antibodies: α-CDA (Sigma, 
SAB1300717 1:250), α-actin (Abcam, ab185058 1:75000). Chemiluminescent detection, 
after incubation of the membranes with appropriate secondary antibodies, was done through 
a CCD camera using the ChemiDoc System (Bio-Rad) with Image Lab software (Bio-Rad, 
version 4.0). For FACS analysis, 5×105 cells were trypsinised, washed in PBS and fixed in 
70% ethanol for 1 h on ice. The pelleted cells were resuspended in 250 μl of staining 
solution (50 μg/ml Propidium Iodide (P4864, Sigma), 0.1 mg/ml RNaseA and 0.05% 
Triton×100) and incubated at 37°C for 40 min. Controls were used for G1 (serum starvation 
overnight) and G2 (0.1μg/μl nocodazole overnight). Fluorescence of 10,000 cells was 
recorded with a FACS Canto flow cytometer (BD Biosciences) and analysed using FlowJo 
software (Version 7.6.5, TreeStar). For immunofluorescence, cells were grown on coverslips 
and fixed with 4% paraformaldehyde for 20 min at room temperature. Cells were washed 
twice in PBS and permeabilised for 10 minutes in 0.2% TritonX-100. After 2 washes in 
PBS, cells were blocked for 1 h in 3% BSA (Sigma Aldrich), dissolved in PBS and 
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incubated with γH2A.X antibody (Millipore, 05-636, 1:500) overnight at 4°C in a 
humidified chamber. Cells were then washed 3 times in PBS and incubated with anti-mouse 
secondary antibody conjugated with Alexa546 (1:400, Life Technologies) and DAPI (Sigma 
Aldrich). Coverslips were then washed 3 times in PBS and mounted with mounting media 
(Vectashield). Tiled pictures were automatically taken with a Zeiss 710 microscope with a 
20× lens. The amount of nuclear fluorescence was quantified using ImageJ.
Gene expression analysis and public datasets
Datasets used in the study: GSE36139 (GPL15308)43, GSE32474 (GPL570)44. Gene 
expression analysis comparing was done on the data from the NCI-60 panel45 as follows. 
Affy HG-U133 Plus 2.0 microarray data was downloaded from CellMiner database (http://
discover.nci.nih.gov/cellminer/loadDownload.do) and cel files were extracted for triplicate 
experiments done on BR:MCF7, ME:MDA_MB_435, BR:MDA_MB_231 and LC:HOP_92 
cell lines. Data was then imported into ArrayStar v11 (DNAStar) and signal normalisation 
and intensity correction was done using RMA Quantile method. Experiment was designed 
by grouping BR:MCF7, ME:MDA_MB_435 cell lines into “Resistant” group and 
BR:MDA_MB_231 and LC:HOP_92 cell lines into “Sensitive” group. Differential 
expression between the groups was determined using the Student’s t-test with Benjamini 
Hochberg multiple testing correction. Genes were called as differentially expressed when 
p<0.01 and fold change >2. The full dataset is included in Extended Table 1. To derive CDA 
expression values in tumours, GPL1530843 and GPL57044 were analysed directly on the 
NCBI portal with GEO2R. p-values were adjusted with Benjamini Hochberg correction.
Toxicology and dose determination in animal experiments
Animal work was done after approval by the UK Home Office and University of Oxford 
Local Ethical review. Three 5-7 week old BALB/cOlaHsd-Foxn1nu/nu (Harlan) mice per 
dose were injected (IP) with 25, 50, 100 mg/kg of 5hmdC and 12.5, 25, 50, 100 mg/kg of 
5fdC. Animals were monitored for any deviations from normal behaviour. At 30 minutes 
post injection, a few drops of blood were collected through tail vein bleeding using 
Microvette CB300 (Sarstedt) to assess the amounts of the compounds in the bloodstream.
Mass spectrometry analysis of serum samples
Serum was isolated by centrifugation of Microvettes according to the recommendations of 
the manufacturer (Sarstedt). The samples were brought up to 200 μl with water and 3 
volumes of methanol, and 150 μl of chloroform added. After intense vortexing, 450 μl of 
water was added, samples were vortexed again and centrifuged at 14,000 rcf for 1 min. The 
aqueous phase containing the soluble molecules was collected and dried in a Speedvac 
(Thermo Scientific). The dried pellets were then resuspended in 10 μl water, then 3 μl 
diluted further into 50 μl of water to load on a RapidFire 360 high throughput sample 
delivery system. The samples were aspirated by vacuum at −40 bar for 400 ms into a 10 μl 
sample loop and loaded onto a graphitised carbon SPE cartridge running buffer 5 mM 
ammonium formate at a flow of 1.5 ml/min. The matrix components not retained on the 
cartridge were diverted to waste for 4500 ms, followed by elution of the retained 
components with 95% acetonitrile 5mM ammonium formate for 4500 ms at a flow of 1 ml/
min, then analysed using an Agilent 6530 QTof mass spectrometer. The SPE was then re-
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equilibrated for 4500 ms with 5 mM ammonium formate. Data was collected in positive ion 
mode using a 2 Gb data collection, Gas temperature 300°C, Drying gas 8 l/min, Nebuliser 
gas 35 psig, Vcap 3500 V, fragmentor voltage 175 V. The amount of nucleoside was 
measured against a standard curve produced by dissolving known amounts of 5hmdC and 
5fdC in foetal bovine serum and processed as indicated above. Data was analysed using an 
Agilent Mass Hunter Qualitative B.06 and Quantitative analysis B.05. Standard curve 
analysis was determined by using a quadratic curve fit algorithm for each nucleoside with an 
R2 >0.98 in all instances.
Nucleoside analysis by mass spectrometry (HPLC-QToF)
Samples were dried in a speed-vac and re-suspended in 10 μl of water. For the analysis by 
HPLC-QToF, a 1290 Infinity UHPLC was fitted with a BEH C18 XP Column, (130Å, 1.7 
μm, 2.1 mm X 150 mm; Waters) and coupled to a 6560 Ion mobility Q-TOF LC/MS mass 
spectrometer (Agilent Technologies, USA) equipped with an Jetstream ESI-AJS source. The 
data were acquired in QToF only mode using positive electrospray ionisation (ESI+). Two 
reference ions, m/z 121.0508 and 922.0097 were used as internal standards. The Dual AJS 
ESI settings were as follows: gas temperature: 150°C, The drying gas: 5 l/min, nebulizer 35 
psig, sheath gas temperature 360°C, sheath gas flow 12 l/min, VCap: 4000 V and nozzle 
voltage: 300 V. The fragmentor of the MS TOF was set to 275 V.
The gradient used to elute the nucleosides started by a 1 minute isocratic gradient composed 
with 99.5 % Buffer A (10 mM ammonium acetate pH 6) and 0.5 % buffer B (composed of 
40 % CH3CN) with a flow rate of 0.350 ml/min and was followed by the subsequent steps:: 
1-2 min, 98.2 % A; 2-16 min 80 % A; 16-18 min 50 % A; 18 -20 min 25 % A; 20.20-21.5 
min 0 % A; 21.5-22.5 min 100% B; 22.5-24.5 min 99.5 % B. The gradient was followed by 
a 5 min post time to re-equilibrate the column.
The raw MS data was analysed using the MassHunter Qual Software package (Agilent 
Technologies, version B7.0), and the masses / retention times used for the characterization of 
nucleosides and their adducts are summarized in Extended table 2. For the identification of 
compounds, raw MS data was processed using the molecular feature extraction function in 
the MassHunter software, followed by metabolite searching through mass / isotope matching 
using the PCDL software (version B.07.00 build 7024.0) and the METLIN database (https://
metlin.scripps.edu/index.php). For each nucleoside, precursor ions corresponding to the M
+H, M+Na, M+K, 2M and base only species were extracted, and the most intense ion 
species observed for each nucleoside was used for quantitation. Identities of peaks eluting at 
4.5 and 5.1 min (Fig. 1b and 3f) are shown in the Extended Data Fig. 9 and 10.
Subcutaneus xenografts
Animal work was done after approval by the UK Home Office and University of Oxford 
Local Ethical review. 106 cells in a 50% suspension of MatriGel (200 μl) were injected into 
5-7 week old BALB/cOlaHsd-Foxn1nu/nu (Harlan) mice, 8 animals per group in each flank 
following the scheme: SN12C/H1299 left, SN12C shCDA8/H1299 dsRedCDA right. When 
the tumours reached palpable size, 8 mice were assigned to each treatment group: PBS, 100 
mg/kg of 5hmdC and 100 mg/kg 5fdC. The compounds were administered every 72 h (4 
Zauri et al. Page 11









doses in total). Tumour size was measured every 3 days by Vernier caliper and the animal 
cohort sacrificed when the cumulative tumour diameter in the first animal reached 12 mm. 
Tumour volume was calculated assuming that the tumours were spheres with the following 
formula: 4/3 π (D/2)3, in which D represents the diameter of the tumour.
Histology
Organs and tumours were collected and immediately 10% formalin fixed for 48 h. They 
were then embedded in wax and 4 μm thick sections cut. All sections were stained with 
H&E. Tumours were additionally stained with a Masson’s Trichrome Stain Kit (Sigma 
Aldrich) according to the manufacturer instructions.
Immunofluorescence of tissues and tumours
4 μm thick sections were subjected to antigen retrieval with a pressure cooker in Tris buffer 
pH 9 (10mM Tris base, 0.05% Tween 20). They were then blocked in 3% BSA in PBS for 
30 minutes and incubated overnight in a humidified chamber at 4°C with the following 
antibodies: γH2A.X (Millipore, 05-636, 1:200) and PH3 (Millipore, 06-570, 1:200) or β-
catenin (BD Transduction Laboratories, 610153, 1:250) and CDA (Sigma Aldrich, 
SAB1300717, 1:100). The slides were then washed vigorously 3 times in PBS and incubated 
for 1 h at room temperature with an appropriate secondary antibody, Alexa546 and 
Alexa488 conjugated (1:400, Life Technologies) and DAPI (Sigma Aldrich). Coverslips 
were then washed 3 times in PBS and mounted with mounting media (Vectashield). Images 
were acquired with a Zeiss 710 confocal microscope with a 20× objective. For quantification 
of DNA damage and proliferation in tumours, tiled images with Z stacks were acquired to 
cover the entire central section of the tumour. Image J was used to quantify the 
immunofluorescence signal.
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Extended Data Figure 1. DNA polymerase and nucleoside kinase activities on modified 
nucleosides
a, MS confirmation of 5hmdC, 5fdC and 5cadC in the purchased nucleosides. b, HPLC-UV 
chromatogram of nucleosides from DNA extracted from H1299 cells transfected with 
5hmdCTP. The abundance of 5hmdC relative to dG is illustrated in the right panel (n=3, 
standard deviation is shown, n.d.= not detected). c, Coomassie-stained SDS-PAGE gel of 
recombinant purified DCK and CMPK1 enzymes used in the study. d, Two-dimensional 
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TLC images of DCK reaction products. Dotted lines indicate reference points, which aid in 
tracking the migration localisation of the nucleosides. The monophosphate in each reaction 
is circled in red (representative picture, n=3). e, schematic map of nucleoside migration on 
two dimensional TLC plate (* indicates a background spot coming from ATP and used as a 
reference point)
Extended Data Figure 2. Stability of the nucleosides and CDA activity
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a,b Quantification of nucleosides by HPLC-UV during 10 days of incubation in water (a) 
and DMEM (b) at 37°C (n=3, standard deviation is shown). c, Representative HPLC-UV 
chromatograms at days 0, 2 and 10 with retention times indicated above each peak. d, Cell 
lines used in the study and their characteristics. e, Western blot showing knock-down of 
CDA by sh-RNA in the SN12C cell line. Right panel illustrates the growth of the cell line 
during treatment with 10 μM 5hmdC (n=3, standard deviation is shown). f, Western blot 
showing expression of CDA in wt and lentivirally transduced MCF7 cell line. Growth curve 
after treatment with 10 μM 5hmdC is shown on the right (n=3, standard deviation is shown). 
g, Coomassie-stained SDS-PAGE gel of recombinant purified CDA enzyme used in this 
study. h, HPLC-UV chromatograms showing the retention times and identity of substrates 
and CDA catalysed products. i, List of Km, kcat and vmax values of catalytic activity of CDA 
catalysing the deamination of cytidine variants.
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Extended Data Figure 3. Mechanism of CDA catalysed deamination of epigenetic nucleosides, 
their cytotoxicity and dUTPase activity
a, Molecular docking of dC, 5hmdC and 5fdC on the CDA active site (PDB 1MQ0). The 
detailed view of the catalytic pocket is shown with the modified nucleoside in the centre. 
Chains A, B and C indicate units of the tetramer, which CDA forms to deaminate four 
nucleosides. Thin yellow lines show compatible distances for the formation of hydrogen 
bonds. b, Growth curves of H1299 and MCF7 cell lines treated with 10 and 1 μM of dC, 
5hmdU and 5fdU over a period of 10 days (n=3, standard deviation is shown). c, Coomassie 
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stained gel demonstrating recombinant purified DUT (MW=18 kDa) and in vitro 
measurements of dUTPase activity using non canonical uridine triphosphates (n=3, standard 
deviation is shown). d, Extracted ion chromatogram of nucleoside standards analysed by 
HPLC-QToF mass spectrometry. Each nucleoside intensity was measured using the merged 
m/z values of the M+H+, M+Na+, M+K+, 2M+H+ and Base+H+ and a symmetric single 
m/z expansion of +/− 0.02. e, The most prominent ion of 5hmdU was identified in 5hmdC 
treated MDA-MB-231 cells.
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Extended Data Figure 4. Mass spectrometry identification of 5fUra and UV quantitation of 
5hmdU in the DNA
a, Extracted ion chromatogram of nucleoside standards with 5fdU analysed by HPLC-QToF 
mass spectrometry (as in Extended data Fig. 3d). b, Weak, but consistent signal of 5fUra is 
identified in DNA of 5fdC treated MDA-MB-231 cells, but not dC treated cells or buffer 
alone. Two representative examples are shown. c, Relative quantification of 5fUra signal 
from three biological MS replicates (standard deviation is shown). d, Relationship between 
measured 5hmdU/T in the DNA of cell lines treated with 10 μM 5hmdC for 3 days and CDA 
expression levels. The cell lines used in this study are in coloured font (n=3, standard 
deviation is shown).
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Extended Data Figure 5. Effect of 5hmdC administration on the cell cycle and DNA damage
a,b, Propidium iodide FACS assay of the cell cycle. Shown are two representative plots (a) 
of MDA-MB-231 cells at day 3 of treatment with dC and 5hmdC (10 μM) and (b) 
quantification for all the cell lines analysed (n=3, standard deviation is shown). Two way 
ANOVA: p (S: 5hmdC vs dC MDA-MB-231) = 0.0027, p (G2-M: 5hmdC vs dC MDA-
MB-231) =0.0149. HOP-92 p<0.0001, p (S: 5hmdC vs dC Capan-2) = 0.0005, p (G2-M: 
5hmdC vs dC Capan-2) <0.0001 (n=3, standard deviation is shown, 10,000 events acquired). 
c, γH2AX immunofluorescence in MDA-MB-231 and H1299 cell lines at day 3 after 
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treatment with 10 μM 5hmdC or dC. Scale bar = 50μm. d, Fraction of cells showing a 
γH2AX signal above background (n=3, standard deviation is shown). ANOVA with Sidak 
correction for multiple comparisons: p (5hmdC vs dC MDA-MB-231) =0.0208, p (5hmdC 
vs dC HOP-92) =0.0135.
Extended Data Figure 6. Quantification of intracellular nucleotides by ion-pair HPLC and 
SMUG1 glycosylase activity
a, Illustrative chromatogram of all standards indicated in b mixed together. b, Retention 
times of nucleotides were determined by analysing each standard separately and are 
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indicated in the table. c, An average relative abundance of NTP and dNTP levels in cells 
treated with dC, 5hmdC and 5fdC (n=3, error bars represent SD). d, Representative 
chromatograms of indicated experiments (blue) overlaid with standards separated on the 
same run (red). e, Typical image of denaturing PAGE electrophoresis of DNA incubated 
with SMUG1 and cleaved with APE1. f, Quantification of the DNA oligonucleotides with 
excised bases. g, expression of SMUG1 and uracil DNA glycosylase (UNG) in 
MDA_MB_231, SN12C and Capan-2 cell lines (Genevestigator).
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Extended Data Figure 7. CDA expression in human cancer and normal tissues and toxicity 
evaluation of 5hmdC and 5fdC in mice
a, CDA overexpression in pancreatic cancer (t-test, p<0.0001). b, CDA expression across a 
panel of cancer (red) versus normal (green) tissues (GENT database). Arrows indicate 
cancer types with an evident difference between normal (N) and cancerous tissues (C). c, 
5hmdC and 5fdC detection in the blood (MS) of intraperitoneally injected mice at 30 
minutes post injection. d, Label free MS quantification of 5hmdC in the blood of animals 
injected with doses of 25, 50 and 100 mg/kg (standard error of the mean is shown, n=3 (100 
mg/ml), n=4 (25 and 50 mg/ml)). e, Immunohistochemistry showing CDA expression in the 
intestine. Scale bar = 50 μm. f, Hematoxylin and eosin staining of the intestine of mice 
injected with PBS and 100 mg/kg of 5hmdC and 5fdC. Tissue was removed 5 days after the 
injection. Scale bar = 50 μm. g, Immunofluorescence evaluation of proliferation (H3PS10) 
and DNA damage (γH2AX) in the intestine of mice treated with PBS and 100 mg/kg of 
5hmdC and 5fdC 5 days after treatment. In parallel, the protocol was done on testis of 
irradiated mice, where positive signals for γH2AX were observed (data not shown). Scale 
bar = 50 μm. h, Weight of the mice plotted over the treatment period (n=16 per group).
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Extended Data Figure 8. Evaluation of wt SN12C cell line and CDA knock-down in a mouse 
xenograft model
a, Schematic illustration of xenograft establishment and treatment with nucleoside variants. 
b, Tumour diameter was measured by Vernier Caliper and volume calculated by assuming 
that tumours were spheres (n=8, standard deviation is shown, two way ANOVA with 
repeated measures and Holm-Sidak correction, p value<0.0001). c, Photos of the dissected 
tumours (* indicates dissected lymph nodes found after histological analysis). d, Western 
blot showing CDA expression in tumours extracted from mice. e, Quantification of 
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proliferation (H3PS10) and DNA damage (γH2AX) using confocal microscopy and ImageJ 
of the central section of the tumour. Scale bar = 50 μm (n=4, standard deviation is shown, 
one way ANOVA, SN12C H3PS10 p=0.0033 for PBS compared with 5hmdC and p=0.0046 
with 5fdC, γH2AX p=0.0003 for PBS compared with 5hmdC and p=0.0436 with 5fdC; 
SN12CshCDA_8 p=0.0130 for PBS compared with 5hmdC). f, 5hmdU quantified from a 
HPLC-UV chromatogram of nucleosides from DNA extracted from tumours of mice treated 
with 5hmdC and PBS (n=4, standard deviation is shown, one way ANOVA p=0.0041).
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Extended Data Figure 9. Identification and quantification of compounds resulting peaks in 
HPLC-UV
a, The abundance of molecule eluting at 5.1 min (5.7 min on the HPLC-QToF) is not 
significantly different between dC and 5hmdC treated samples. It is a common component 
of DNA hydrolysis buffer. b, 5mCyt in the DNA does not change after treatment with 
5hmdC. Identity of 5mdC in the samples is confirmed by HPLC-QToF MS.
Extended Data Figure 10. Identification and quantification of compounds resulting peaks in 
HPLC-UV
Compound eluting at 4.5 min (5.0 min on the HPLC-QToF) is an abundant component of 
DNA hydrolysis buffer generating a m/z of 202.18.
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Extended data Table 1
Refer to Web version of this manuscript for the associated 
table file.
Extended data Table 2
Name Formula RT m/z Mass Mass (DB) Diff (DB, mDa)
2′deoxycytidine C9 H13 N3 O4 2.854 228.1019 227.0941 227.0906 −3.48
2′-Deoxy-5-(hydroxymethyl)cytidine C10 H15 N3 O5 3.231 258.1139 257.1061 257.1012 −4.92
2′-Deoxy-5-(hydroxymethyl)uridine C10 H14 N2 O6 4.253 259.0967 258.0889 258.0852 −3.76
2′-Deoxyuridine C9H12N2O5 4.074 229.0883 228.0805 228.0746 −5.9
2′-Deoxy-5-methylcytidine C10 H15 N3 O4 5.845 242.117 241.1092 241.1063 −2.94
2′-Deoxyguanosine C10 H13 N5 O4 6.055 268.1072 267.1 267.0968 −3.23
2′-Deoxy-5-formylcytidine C10 H13 N3 O5 6.995 256.097 255.0892 255.0855 −3.73
2′-Deoxythymidine C10 H14 N2 O5 7.564 243.1017 242.0939 242.0903 −3.59
2′-Deoxyadinosine C10 H13 N5 O3 9.331 252.112 251.1049 251.1018 −3.04
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Figure 1. DNA polymerase and nucleoside kinase activities on modified nucleosides
a, HPLC-UV (260 nm) chromatogram of nucleosides mixed in equimolar amounts. b, 
HPLC-UV examination of nucleosides derived from DNA extracted from MDA-MB-231 
cells nucleoporated with 5hmdCTP. c, The abundance of 5hmdC relative to dG in 
nucleoporated MDA-MB-231 (n=3, standard deviation is shown, n.d. = not detected). d, 
5hmdCTP incorporation assessed by in vitro replication assay (IVRA) performed in HeLa 
cells, measured by HPLC-UV (n=5, standard deviation is shown, n.d.= not detected). e, TLC 
separation of reaction products of DCK and CMPK1 kinases, which were supplied with 
different modified cytidine substrates. xMP indicates cytidine monophosphates; xDP 
indicates cytidine diphosphates.
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Figure 2. Identification of cytidine deaminase (CDA) overexpression as a primary determinant 
for cytotoxic action of natural cytidine variants
a, Ratio of live cells after 10 days of treatment with 5hmdC versus dC (n=3, standard 
deviation is shown). b, Growth curves of MDA-MB-231 and H1299 cell lines treated with 3 
different concentrations of dC, 5hmdC and 5fdC over a period of 10 days (n=3, standard 
deviation is shown). c, Volcano plot illustrating analysis of gene expression of MDA-
MB-231 and HOP-92 versus MCF-7 and MDA-MB-435 cell lines. Shown in orange are the 
genes, which are significantly different between the groups (p<0.01; >2 fold change). Dots 
in black show nucleoside transporters (SCL29A1, SLC29A2, SLC29A3, SLC29A4, 
SLC28A1, SLC28A2, SLC28A3) and kinases (DCK, CMPK1). d, CDA expression levels 
from NCI60 and CCLE global gene expression datasets for different cancer cell lines. e, 
Western blot confirming CDA overexpression in SN12C and Capan-2 cell lines. Growth 
curves of Capan-2 and SN12C after treatment with 10 μM 5hmdC, 5fdC and dC (n=3, 
standard deviation is shown).
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Figure 3. Molecular mechanism of CDA-dependent cytotoxicity of cytidine variants
a, Western blot showing knock-down of CDA by sh-RNA in the MDA-MB-231 cell line. 
Right panel illustrates growth curves of derived stable cell lines after treatment with 10 μM 
5hmdC (n=3, standard deviation is shown). (0) and (8) indicates two different sh-RNA 
constructs used for the experiments. b, Western blot showing overexpression of CDA after 
lentiviral transduction of H1299 cells with a construct overexpressing CDA (CDA_dsRed). 
The right panel shows the growth curve after treatment with 10 μM 5hmdC (n=3, standard 
deviation is shown). c, CDA activity fitted to the Michaelis-Menten model. The right panel 
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shows a zoomed-in curve, when 5hmdC was used as a substrate. d, kcat values of CDA 
supplied with cytidine variants. e, TLC separation of reaction products of TK1 and DTYMK 
kinases, which were exposed to different modified uridine substrates. xMP indicates 
monophosphates and xDP indicates diphosphates. f, HPLC-UV chromatogram of 
nucleosides from DNA of MDA-MB-231 cells treated with 10 μM 5hmdC or dC for 3 days. 
The right panel shows the abundance of 5hmdU relative to T (n=3, standard deviation is 
shown, t-test, p=0.0057). g, γH2AX immunofluorescence in MDA-MB-231 and H1299 cell 
lines at day 3 after treatment with 10 μM 5hmdC or dC. Scale bar = 50 μm. Below are 
quantifications of cells showing positive signals (n=3, standard deviation is shown, t-test, 
p=0.0017).
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Figure 4. In vivo evaluation of cytidine variants and the proposed model of epigenetic nucleoside 
variants in the nucleoside recycling pathway
a, wt and CDA_dsRed overexpressing H1299 cells were mixed at equal ratios and exposed 
to the indicated variants of cytidine. Representative histogram (left) and quantitation of the 
results (right) are shown (n=3, standard deviation is shown, 10,000 events recorded). Lower 
concentration of 5fdC was used to demonstrate higher cytotoxic potency. b, Schematic 
illustration of xenograft establishment and treatment with nucleoside variants. c, Volume of 
tumours, calculated by assuming that tumours were spheres with their diameters measured 
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using Vernier calipers (n=8 in 5fdC and n=7 in 5hmdC experiments, standard deviation is 
shown, two-way ANOVA with repeated measures Holm-Sidak correction, p<0.0001). 
Dissected tumours are illustrated in the photo below. d, Evaluation of proliferation 
(immunofluorescence, H3PS10) and DNA damage (immunofluorescence, γH2AX) in 
dissected tumour samples. Scale bar = 50 μm (n=4, standard deviation is shown, one way 
ANOVA, H3PS10 p=0.0057, γH2AX p(5hmdC vs PBS)=0.0491, p(5fdC vs PBS)=0.0001). 
e, Model of metabolism of epigenetic nucleoside variants.
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